Background-No treatment strategies have been demonstrated to be beneficial for the population for patients with heart failure (HF) and preserved ejection fraction (EF). Methods and Results-The CardioMEMS Heart Sensor Allows Monitoring of Pressure to Improve Outcomes in NYHA Class III Heart Failure Patients (CHAMPION) trial was a prospective, single-blinded, randomized controlled clinical trial testing the hypothesis that hemodynamically guided HF management decreases decompensation leading to hospitalization. Of the 550 patients enrolled in the study, 119 had left ventricular EF ≥40% (average, 50.6%), 430 patients had low left ventricular EF (<40%; average, 23.3%), and 1 patient had no documented left ventricular EF. A microelectromechanical system pressure sensor was permanently implanted in all participants during right heart catheterization. After implant, subjects were randomly assigned in single-blind fashion to a treatment group in whom daily uploaded pressures were used in a treatment strategy for HF management or to a control group in whom standard HF management included weight-monitoring, and pressures were uploaded but not available for investigator use. The primary efficacy end point of HF hospitalization rate >6 months for preserved EF patients was 46% lower in the treatment group compared with control (incidence rate ratio, 0.54; 95% confidence interval, 0.38-0.70; P<0.0001). After an average of 17.6 months of blinded follow-up, the hospitalization rate was 50% lower (incidence rate ratio, 0.50; 95% confidence interval, 0.35-0.70; P<0.0001). In response to pulmonary artery pressure information, more changes in diuretic and vasodilator therapies were made in the treatment group. Conclusions-Hemodynamically guided management of patients with HF with preserved EF reduced decompensation leading to hospitalization compared with standard HF management strategies. Clinical Trial Registration-URL: http://www.clinicaltrials.gov. Unique identifier: NCT00531661.
A cutely decompensated chronic heart failure (HF) results in ≈1 million hospital admission in the United States yearly and contributes to >3 million admissions. 1, 2 Registry studies suggest that ≈50% of patients hospitalized with decompensated HF have preserved left ventricular ejection fraction (LVEF). 3 This group represents a significant clinical challenge as there are no evidence-based medical treatments proven effective in modifying disease progression or preventing hospitalization. 4 The only consensus recommendations for this syndrome are to control blood pressure and body fluid volume. 4 Body volume changes and shifts are of prime concern as congestive symptoms are present in >90% of patients admitted for decompensated HF regardless of EF. 3 Early experience with implantable hemodynamic monitoring suggests that elevation in cardiac filling pressures precedes HF events by ≥1 to 2 weeks in patients with both reduced EF and preserved EF. 5, 6 Traditional tools to monitor volume, including patient self-assessment and daily weight measurement, are limited by inaccuracies and intermittent assessments. 7, 8 management based on frequently acquired pulmonary artery (PA) pressures significantly reduces hospital admissions in a group of 550 patients with HF associated with both preserved and reduced systolic function. 9 This trial was unique in that it prospectively tested a specific medical management strategy based on remotely obtained PA pressures. 10 This part of the CHAMPION protocol was designed to address clinical concerns about integrating new data streams into HF management systems. 11 The current report provides details about the prospectively identified subgroup of the CHAMPION trial characterized by LVEF ≥40% and further evaluates clinical outcomes in patients with LVEF ≥50%.
Methods

Trial Design
The CHAMPION trial was a prospective, multicenter, randomized, single-blinded, implanted control clinical trial. The details of trial design 10 and principle results have been reported previously. 9 In brief, 550 patients with persistent New York Heart Association class III HF symptoms, despite maximal device and medical therapies, who required hospitalization for decompensation in the previous 12 months were enrolled in the trial. Patients were enrolled without regard to EF. All patients were implanted with a microelectromechanical system-based PA pressure sensor during right heart catheterization. After implantation, the patients were randomly assigned to a treatment group in which remotely obtained information from the implanted sensor was added to standard HF management. The control group received standard of care HF management, but measured pressures were not made available to investigators. Pressures were measured daily in the patients' homes and uploaded to an interactive database with display of pressures graphically in the treatment group for investigator decision making. All patients provided informed consent to volunteer for this trial and the protocol was approved by each site's institutional review board.
Investigators were asked to review uploaded PA pressure information on a web-based information system at least weekly. In addition to online pressure review, the database had an automatic email notification system that initiated a contact to the study personnel if the daily pressures were outside of the user defined range. The default ranges for the automatic notification system were initially set as the PA pressure targets for the trial, but could be changed by the investigator.
These pressure monitoring tools were used to implement a protocoldefined medical strategy, based on data from previous hemodynamic monitoring trials, 5, 6, [12] [13] [14] [15] [16] to manage PA pressures. Initially, hemodynamic information was available in both the treatment and control groups at the time of the right heart catheterization and implantation of the device. The protocol identified optimal filling pressure ranges 10 and considered patients with elevated pulmonary pressures first to be volume overloaded. The investigators were instructed to increase diuretic therapy to lower pressures to goal. Vasodilator therapy (including long-acting nitrates and hydralazine) was suggested for patients who had persistently elevated pressures despite maximizing diuretic therapy as this group is known to have higher hospital admission risks. 12 Medication changes based on pressure measurements were recorded in a case report form and collected.
Efficacy End Points
The primary efficacy end point was rate of HF hospitalizations measured at 6 months and compared between treatment and control groups. All patients remained in their original randomized group until the last patient completed 6-month follow-up allowing the trial to provide long-term randomized and blinded efficacy data.
The protocol defined a prespecified subgroup analysis based on LVEF considering patients with an EF ≥40% as preserved and those with an EF <40% as reduced EF. The definition of these prespecified subgroups were based on the lack of consensus on definitions of HF with preserved EF (HFpEF) and the lack of clear consensus about guideline-recommended medical therapies for patients with LVEF ≥40%. Subsequently, after the trial was designed and implemented, the 2013 American Heart Association/American College of Cardiology HF guidelines provided clearer consensus about defining patients with HFpEF using an LVEF ≥50%. This report outlines the results using the prespecified subgroup with LVEF ≥40% and also provides a post hoc analysis of patients with LVEF ≥50%. Unless otherwise stated, references to patients with preserved EF will defer to the prespecified CHAMPION criteria of EF ≥40%.
All primary end point events throughout the trial and follow-up period were independently adjudicated by a blinded committee of HF cardiologists. An independent data safety and monitoring committee oversaw the trial and performed 1 unblinded interim review when one-half of the intended enrollment reached 6 months of follow-up. Electronic data capture was maintained by an independent data center. The principal investigators of the trial (P.B.A., W.T.A.) and authors had full access to data generated and provide independent interpretation of the results.
Statistical Methods
Study outcomes are presented using descriptive statistics (n, mean, SD, and median). Baseline variables were analyzed for balance between groups as follows: continuous variables were evaluated using a Wilcoxon rank-sum test, categorical variables were evaluated using a Fisher exact test. HF hospitalization rates were analyzed using the prespecified negative binomial regression methodology, which contained terms for duration in trial and group. Medication changes were analyzed using Wilcoxon rank-sum test and medication dose used the 2-group t test. α value of 0.05 was used for statistical significance and all tests were 2-sided unless stated otherwise.
Analysis of PA Pressure Changes Over Time
Methods used to analyze changes in pressures between 2 discrete time points (eg, at baseline and the end of the 6-month follow-up period) are limited in their ability to characterize the dynamic nature of PA pressure changes because daily PA pressure variability reflects the dynamic nature of management and clinical status. For example, pressures increase when patients become congested and decrease as they respond to medication changes. Therefore, the CHAMPION protocol included a preplanned evaluation of pressures using an area under the curve methodology (unit of measure=mm Hg days) to estimate the total sum increase or decrease in PA pressure during the entire 6-month follow-up period relative to baseline pressures.
Changes in PA pressure were also evaluated before HF hospitalizations and compared with changes in PA pressure before non-HF hospitalizations. The patient's baseline pressures were defined as the average PA pressures from days 21 to 8 before hospitalization. Average baseline pressures were compared with mean PA pressures from days 7 to 1 before the hospitalization. Pressure changes were then compared between hospitalizations adjudicated HF and those deemed not related to HF.
Results
Patient Characteristics
Five-hundred fifty patients were successfully implanted with the pressure sensor and randomized in the CHAMPION trial. One hundred nineteen subjects (22%) had preserved EF (EF ≥40%; average 51%), whereas 66 patients had LVEF ≥50% at enrollment. Four hundred thirty patients had an EF <40% (average, 23%) and 1 patient did not have an EF documented at enrollment. This patient was not included in the current evaluation. Sixty-two patients in the preserved EF group were randomized to the treatment group and the remaining 57 to the control group. Of the patients with LVEF ≥50%, 35 patients were randomized to treatment and 31 to control. Table 1 provides details of patient demographics, but in summary, subjects with preserved EF were older, more often white females with higher body mass indexes than subjects with low EF. Characteristics of patients with LVEF ≥50% are shown in Table 2 and are similar to the entire group with LVEF ≥40%. Renal function was not different between the groups. Systemic blood pressure was higher in preserved EF patients, but PA pressures were lower at baseline. Pulmonary capillary wedge pressure was lower in the preserved EF group and cardiac output was higher compared with the low EF group at the initial right heart catheterization. LVEF averaged 50.6% in the preserved group and 23.3% in the low EF group.
Comorbidities were similar between the EF groups except for a higher percentage of patients reporting diabetes mellitus and cerebrovascular disease in the preserved EF group (Table 3) , whereas low EF patients had higher rates of previous myocardial infarction and hypotension (Table 3 ). Baseline medical therapies were similar between the preserved and reduced EF groups as shown in Table 4 . No differences in baseline medications were found between treatment and control groups of either EF category.
Primary Efficacy: HF Hospitalization Rates
The rate of HF hospitalizations was significantly lower in the preserved EF treatment group compared with the control group for 6 months of randomized study. There were 11 HF hospitalizations in the 62 treatment group patients (0.18 hospitalizations/patient-6 months) compared with 19 HF hospitalizations in the 57 control group patients (0.33 hospitalizations/patient-6 months) resulting in a significant relative risk reduction of 46% (incidence rate ratio [IRR], 0.54; 95% confidence interval [CI], 0.38-0.70; P<0.0001; Table 5 ).
The treatment effect was consistent in patients with LVEF ≥50% There were 9 HF hospitalizations in the 35 treatment group patients (0.18 hospitalizations/patient-6 months) compared with 10 HF hospitalizations in the 31 control group patients (0.35 hospitalizations/patient-6 months) resulting in a significant relative risk reduction of 50% (IRR, 0.50; 95% CI, 0.29-0.86; P=0.0129; Table 5 ).
Reduced EF treatment group patients also had a significantly lower rate of HF hospitalizations compared with the control group. There were 73 HF hospitalizations in the 208 treatment group patients (0.36 events/patient-6 months) and 101 HF hospitalizations in the 222 control group patients (0.47 events/ patient-6 months) resulting in a significant relative risk reduction of 24% (IRR, 0.76; 95% CI, 0.61-0.91; P=0.0085; Table 5 ).
The reduction in HF hospitalizations in the preserved EF treatment group was greater during the entire duration of follow-up. There were 29 HF hospitalizations after 17.6 months of average follow-up in the preserved EF treatment group for an annualized rate of 0.43 events/patient-year. This was compared with 59 HF hospitalizations in the control group for a rate of 0.86 events/ patient-year and a relative risk reduction of 50% (IRR, 0.50; 95% CI, 0.35-0.70; P<0.0001; Figure [A] ). This resulted in a number needed to treat per year to prevent 1 HF hospitalization of 2.
After 17.6 months of follow-up in the LVEF ≥50% patients there were 13 HF hospitalizations in the treatment group for an annualized rate of 0.41 events/patient-year compared with 31 HF hospitalizations in the control group for a rate of 1.39 events/patient-year resulting in a relative risk reduction of 70% (IRR, 0.30; 95% CI, 0.18-0.48; P<0.0001; Table 6 ). The treatment group of the low EF subjects also had fewer HF hospitalizations after 17.6 months of average randomized follow-up with 153 HF hospitalizations (0.67 events/patientyear) compared with 220 HF hospitalizations in the control group (0.90 events/patient-year; Figure [B] ) for a significant relative risk reduction of 26% (IRR, 0.74; 95% CI, 0.63-0.89; P=0.0010; Table 6 ).
When the ≥50% cohort was analyzed during the 6-month period, the treatment and control groups experienced numerically similar number of HF hospitalizations. However, the treatment group events occurred in more patients and thus had a longer combined follow-up compared with the control group events, which occurred in fewer patients and thus a shorter combined follow-up. Thus, events (numerator) during longer total follow-up in the treatment group (denominator) results in a lower rate than a similar number of events in the control group during a shorter total follow-up. When the ≥50% cohort was analyzed during the full duration of randomized follow-up of 18 months, the follow-up duration was similar between treatment and control groups and thus the number of events between groups better corresponds to the event rates between groups.
Proportion of Patients Hospitalized for HF
The reduction in the proportion of patients hospitalized for HF in the treatment group was also consistent with the reduction in HF hospitalizations rates. During the 6-month primary end point period, 8 of 62 treatment group patients with preserved EF were hospitalized for HF (12.9%) compared with 13 of 57 control group patients with preserved EF (22.8%) resulting in an absolute reduction of 9.9%. For patients with reduced EF, 47 of the 208 treatment group patients (22.6%) were hospitalized for HF compared with 67 of the 222 control group patients (30.2%) resulting in an absolute reduction of 7.6%. During the full duration of follow-up, 18 of the 62 treatment group patients with preserved EF (29.0%) were hospitalized for HF compared with 22 of the 57 control group patients with preserved EF (38.6%) resulting in an absolute reduction of 9.6%. For patients with reduced EF, 73 of the 208 treatment group patients (35.1%) were hospitalized for HF compared with 94 of the 222 control group patients (42.3%) resulting in an absolute reduction of 7.2%.
Time to first HF hospitalization analysis in the preserved EF and reduced EF groups demonstrated a meaningful delay in disease progression with hazard ratio point estimates of 0.54 in the preserved EF group (95% CI, 0.22-1.30) and 0.73 in the reduced EF group (95% CI, 0.51-1.07). However, excluding repeat HF hospitalizations, as is required for time to first event analyses, significantly reduced the power for these analyses as demonstrated by the wider CIs compared with the repeat HF hospitalization rate analyses.
Medication Changes
During the 6-month primary end point period, preserved EF treatment group subjects received more intensive medical management compared with preserved EF control group subjects (average of 8.0 HF medication changes for a total of 495 in treatment subjects versus an average of 4.1 HF medication changes for a total of 232 in control subjects; P<0.0001). Similar findings were also observed in reduced EF subjects (average of 9.5 HF medication changes for a total of 1973 in treatment subjects versus an average of 3.7 HF medication changes for a total of 825 in control subjects; P<0.0001; Table 7 ). The differences in medical management between treatment and control group subjects were because of medication changes in response to elevated PA pressure ( Table 8 ). Most of the 260 medication changes (73.5%; n=191) in response to elevated PA pressures in the treatment group involved an increase or decrease in loop or thiazide diuretic dosing (Table 8 ). Nitrates and hydralazine changes represented 33 (12.7%) of the responses to elevated PA pressures. Similar findings were also observed in reduced EF subjects. Most of the 1002 medication changes (64.9%; n=650) in response to elevated PA pressures in the treatment group involved a loop or thiazide diuretic (Table 8 ). Nitrates and hydralazine changes represented 110 (12.6%) of the responses to elevated PA pressures (Table 8) .
Diuretic changes in response to elevated PA pressures typically included increases in dose or frequency during a 2-to 3-week time period. When PA pressures were adequately lowered in response to these changes, physicians typically reduced the dose and frequency back to the patient's baseline regimen. As a result of this dynamic process, treatment group patients received diuretic adjustment only when hemodynamically warranted for limited time intervals. Although the change in total daily dose of diuretics and nitrates, when evaluated at baseline and the end of the 6-month time period, does not fully characterize this dynamic process, this analysis does provide a snapshot of how access to PA pressures resulted in differential treatment profiles between the treatment and control groups (Tables 9 and 10 ).
For treatment group patients with preserved EF, the total daily dose of loop diuretics was increased from baseline by 52.1 mg (furosemide equivalent) compared with only 0.4 mg in control group patients (P=0.0045; Tables 9 and 10 ). The change in total daily dose from baseline for nitrates was not different between treatment group and control group preserved EF patients. For patients with reduced EF, the total daily dose of nitrates was increased from baseline by 18.2 mg compared with only 2.6 mg in control group patients (P=0.0230). The change in total daily dose from baseline for loop diuretics was not different between treatment group and control group reduced EF patients (Tables 9 and 10 ).
Changes in PA Pressure
At device implantation and randomization, patients with preserved EF had similar PA mean pressures between the treatment and control groups (27.1 versus 26.5 mm Hg; P=0.5327; Table 1 ). Using area under the curve methods, treatment group patients had a median reduction of −3.0 mm Hg days versus an increase of 97.7 mm Hg days in control group patients during the 6 months of primary follow-up.
In patients with preserved EF, the increase in average mean PA pressure was 3.4±4.6 mm Hg before a HF hospitalization compared with 0.7±4.8 mm Hg before a non-HF hospitalization (P=0.0174). The same pattern was observed in patients with reduced EF. The increase in mean PA pressure was 1.3±5.6 mm Hg before a HF hospitalization compared with −0.3±5.5 mm Hg before a non-HF hospitalization (P=0.0034).
Discussion
Patients with HF and preserved LVEF were the only prespecified subgroup analysis in the CHAMPION trial. Significant and clinically meaningful reductions in hospitalization rates were accomplished in the patient with HFpEF group by primarily adjusting diuretic therapy to maintain control of remotely monitored PA pressure measurements. Hospitalization reductions were similar between patients in the prespecified subgroup with LVEF ≥40% and the additional analysis performed in the group with LVEF ≥50%. Hospitalization reductions were significant after 6 months of hemodynamic-guided care and at an even greater magnitude after an average of 17.6-month follow-up (relative rate reduction 50%; number needed to treat 2). This benefit occurred in addition to excellent HF management using traditional tools, the intensity of which is suggested by lower than expected control group event rates. Hemodynamic-guided management using daily PA pressure measurements is the one of the first successful strategies to improve the outcome of patients with preserved EF HF syndromes. Reduced HF hospitalization rates were the result of a planned and uniform treatment strategy tested in the CHAMPION trial. This approach was developed in based on data from previous hemodynamic monitoring trials demonstrating that patients who lived at high filling pressures were at highest hospitalization risks. [12] [13] [14] [15] [16] In previous implantable hemodynamic monitoring trials it was assumed that patients who seemed clinically stable at high filling pressures did not need intervention to lower filling pressures unless the pressures rose further. 16 In a retrospective analysis it was clear that high pressures could and should be lowered, and this reduction of baseline plateau levels reduced HF hospitalization risks. 12 Therefore, the main focus of the protocol-directed treatment strategy in CHAMPION was to lower pressures to near normal levels first using diuretics and then adding vasodilators if pressures were persistently high. The CHAMPION trial was the first hemodynamic monitoring trial to provide a protocol-directed treatment strategy to actively lower elevated PA pressures using specific guidelines for diuretic and vasodilator therapy.
Pathophysiologic Insights
All definitions of HFpEF rely primarily on the presence of pulmonary congestion symptoms (dyspnea on exertion, paroxysmal nocturnal dyspnea, orthopnea, or fatigue), which are unexplained by other comorbid conditions. At the time the CHAMPION trial was designed, there was lack of clear consensus about which LVEF should be used to define patients with HFpEF. In addition, there was clear consensus that patients with LVEF <40% should be treated with guideline-directed medical therapies, but lack of consensus about medical management existed when the LVEF was ≥40%. Subsequently, data emerged supporting clearer consensus about definition and appropriate medical therapies for patients with HF and EF levels >40%. Some controversy exists about EF with 2013 American College of Cardiology/American Heart Association HF guidelines, suggesting that HFpEF with LVEF ≥50% is clinically similar to borderline LVEF (41%-49%), 4 whereas guidelines from the European Society of Cardiology defines HFpEF based on LVEF ≥50% with objective evidence of abnormal LV filling. 17 In addition to definitional issues, the pathophysiology of HFpEF is heterogeneous, with abnormalities in multiple discrete components of LV function leading to abnormal cardiovascular homeostasis. 18 Abnormalities at the cellular, organ, and system levels are described 19 and elucidate why HFpEF occurs, but data from this report and other evaluations of preserved EF patients with implantable hemodynamic technology 6 suggest that the symptoms of LV failure with preserved or reduced EF arise from similar mechanisms. The final common pathway of congestion in patients with HF, regardless of EF, is related to progressive increases in filling pressures. Targeting these pressures with medical management, primarily focusing on vascular volume using frequent diuretic dose changes, maintains clinical stability and successfully avoids hospitalizations compared with excellent clinical management using traditional tools alone (control group).
It is important to recognize that the majority of medications changed in the CHAMPION trial preserved EF group were diuretics. The treatment protocol called for careful addition of vasodilator therapy if required to further lower PA pressures after volume contraction with diuretics failed to reach pressure goals. In reality, changes in vasodilator therapy represented only 12% of medication changes in response to pressure information. Furthermore, there was no difference in nitrate dosing after 6 months of pressure-guided care. Patients with HFpEF respond differently to acute sodium nitroprusside infusion with more systemic hypotension and greater possibility of reduced stroke volume compared with patients with reduced EF. 20 Therefore, it is important to exercise caution when initiating chronic vasodilator therapy in patients with HFpEF, in general, and provision of daily filling pressures may enhance safety and efficacy of this therapeutic intervention.
The CHAMPION trial findings provide further insight into the components of successful outpatient management of patients with HFpEF and reiterate how difficult volume management can be using traditional tools. Direct access to filling pressures allowed appropriate increases and decreases in the intensity of diuretic intervention based on physiological need. Appropriate use of diuretic therapy was associated with significant reduction in the need for hospitalization during a long-term clinical follow-up period. In fact, the rate of hospitalizations was similar between treatment and control groups for the first 3 months of randomized treatment. This interesting observation was likely reflected the impact of investigators having hemodynamic information in the control group because all patients underwent right heart catheterization at baseline. This concept is consistent with the ESCAPE (Evaluation Study of Congestive Heart Failure and Pulmonary Artery Catheterization Effectiveness) trial evidence that invasive hemodynamic snapshots in patients with HF may affect short-term outcomes, 21 but consistent reduction of hospitalization rates for longer periods require frequent re-evaluation of hemodynamic status to ensure clinical stability.
Limitations
The CHAMPION trial's prespecified subgroup analysis was designed to include patients with LVEF above and below 40%. A supplemental post hoc analysis of those patients with LVEF ≥50% provides assurance that outcomes are similar in that group. Patients with LVEF ≥50% were younger and mostly men, which is different from populations typically characterized as patients having HFpEF. Although significant differences in outcomes were seen in the LVEF ≥50% group, the number of events was small. This, coupled with the retrospective analysis, strongly supports the hypothesis that hemodynamic-guided HF management is superior to traditional strategies, but more study is warranted to determine the true magnitude of effect. The CHAMPION trial includes the largest group of preserved EF patients followed with implantable hemodynamic monitors, but the numbers of patients are still too small to adequately evaluate predefined secondary end points.
During regulatory evaluation of the CHAMPION trial, the US Food and Drug Administration raised concerns that the trial's design may have introduced unintended bias in the treatment group because of interaction between the sponsor, PIs and site investigators. 22 This important issue was investigated for a 2-year period of time, which included an independent review of all communications between the sponsor and sites along with 3 separate analyses to determine whether bias occurred and what clinical impact, if any, it may have had on the study results. The entirety of evidence demonstrated that no meaningful bias was created by the way the trial was performed. 23 After careful evaluation of these important issues, the USFDA provided regulatory approval of the device to reduce HF hospitalizations for the population studied. 24 
Conclusions
The CHAMPION trial demonstrated that hemodynamic-guided medical management of patients with HF and LVEF ≥40% reduced HF hospitalizations by 50% compared with traditional treatment strategies. In the CHAMPION trial clinical stability was better maintained in patients with LVEF ≥40% using hemodynamic-guided HF management resulting in lower hospitalizations. Further studies are warranted in patients with HF and LVEF ≥50%, but data from the CHAMPION trial support the hypothesis that these patients also may benefit from this strategy.
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